Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Evidence that melatonin downregulates Nedd4-1 E3 ligase and its role in cellular survival.

Yalcin E, Beker MC, Turkseven S, Caglayan B, Gurel B, Kilic U, Caglayan AB, Kalkan R, Baykal AT, Kelestemur T, Kilic E.

Toxicol Appl Pharmacol. 2019 Jul 17:114686. doi: 10.1016/j.taap.2019.114686. [Epub ahead of print]

PMID:
31325559
2.

Can a 1-day clear liquid diet with a split -dose polyethylene glycol overcome conventional practice patterns during the preparation for screening colonoscopy?

Özer Etik D, Suna N, Gündüz C, Bostan A, Özdemir A, Gürel BY, Yenişekerci E, Boyacıoğlu AS.

Turk J Gastroenterol. 2019 Jul 1. doi: 10.5152/tjg.2019.19071. [Epub ahead of print]

3.

Molecular signatures of chronic periodontitis in gingiva: A genomic and proteomic analysis.

Guzeldemir-Akcakanat E, Alkan B, Sunnetci-Akkoyunlu D, Gurel B, Balta VM, Kan B, Akgun E, Yilmaz EB, Baykal AT, Cine N, Olgac V, Gumuslu E, Savli H.

J Periodontol. 2019 Jun;90(6):663-673. doi: 10.1002/JPER.18-0477. Epub 2019 Feb 20.

PMID:
30653263
4.

Neonatal Neurodegeneration in Alzheimer's Disease Transgenic Mouse Model.

Mazi AR, Arzuman AS, Gurel B, Sahin B, Tuzuner MB, Ozansoy M, Baykal AT.

J Alzheimers Dis Rep. 2018 Apr 12;2(1):79-91. doi: 10.3233/ADR-170049.

5.

Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency.

Zafeiriou Z, Bianchini D, Chandler R, Rescigno P, Yuan W, Carreira S, Barrero M, Petremolo A, Miranda S, Riisnaes R, Rodrigues DN, Gurel B, Sumanasuriya S, Paschalis A, Sharp A, Mateo J, Tunariu N, Chinnaiyan AM, Pritchard CC, Kelly K, de Bono JS.

Eur Urol. 2019 Jan;75(1):184-192. doi: 10.1016/j.eururo.2018.09.048. Epub 2018 Oct 16.

6.

Effect of Preanalytic Variables on an Automated PTEN Immunohistochemistry Assay for Prostate Cancer.

Guedes LB, Morais CL, Fedor H, Hicks J, Gurel B, Melamed J, Lee P, Gopalan A, Knudsen BS, True LD, Scher HI, Fine SW, Trock BJ, De Marzo AM, Lotan TL.

Arch Pathol Lab Med. 2019 Mar;143(3):338-348. doi: 10.5858/arpa.2018-0068-OA. Epub 2018 Oct 8.

PMID:
30295067
7.

Identification of candidate biomarkers in converting and non-converting clinically isolated syndrome by proteomics analysis of cerebrospinal fluid.

Timirci-Kahraman O, Karaaslan Z, Tuzun E, Kurtuncu M, Baykal AT, Gunduz T, Tuzuner MB, Akgun E, Gurel B, Eraksoy M, Kucukali CI.

Acta Neurol Belg. 2019 Mar;119(1):101-111. doi: 10.1007/s13760-018-0954-4. Epub 2018 Jun 5.

PMID:
29873030
8.

Scoring Idiopathic Granulomatous Mastitis: An Effective System for Predicting Recurrence?

Yılmaz TU, Gürel B, Güler SA, Baran MA, Erşan B, Duman S, Utkan Z.

Eur J Breast Health. 2018 Apr 1;14(2):112-116. doi: 10.5152/ejbh.2018.3709. eCollection 2018 Apr.

9.

Early Stage Alterations in CA1 Extracellular Region Proteins Indicate Dysregulation of IL6 and Iron Homeostasis in the 5XFAD Alzheimer's Disease Mouse Model.

Gurel B, Cansev M, Sevinc C, Kelestemur S, Ocalan B, Cakir A, Aydin S, Kahveci N, Ozansoy M, Taskapilioglu O, Ulus IH, Başar MK, Sahin B, Tuzuner MB, Baykal AT.

J Alzheimers Dis. 2018;61(4):1399-1410. doi: 10.3233/JAD-170329.

PMID:
29376847
10.

Time-of-Day Dependent Neuronal Injury After Ischemic Stroke: Implication of Circadian Clock Transcriptional Factor Bmal1 and Survival Kinase AKT.

Beker MC, Caglayan B, Yalcin E, Caglayan AB, Turkseven S, Gurel B, Kelestemur T, Sertel E, Sahin Z, Kutlu S, Kilic U, Baykal AT, Kilic E.

Mol Neurobiol. 2018 Mar;55(3):2565-2576. doi: 10.1007/s12035-017-0524-4. Epub 2017 Apr 18.

PMID:
28421530
11.

PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance.

Trock BJ, Fedor H, Gurel B, Jenkins RB, Knudsen BS, Fine SW, Said JW, Carter HB, Lotan TL, De Marzo AM.

Mod Pathol. 2016 Jul;29(7):764-71. doi: 10.1038/modpathol.2016.63. Epub 2016 Apr 15.

12.

Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trial.

Winchester DA, Gurel B, Till C, Goodman PJ, Tangen CM, Santella RM, Johnson-Pais TL, Leach RJ, Thompson IM, Xu J, Zheng SL, Lucia MS, Lippman SM, Parnes HL, Isaacs WB, Drake CG, De Marzo AM, Platz EA.

Prostate. 2016 May;76(6):565-74. doi: 10.1002/pros.23147. Epub 2016 Jan 15.

13.

Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial.

Murtola TJ, Gurel B, Umbehr M, Lucia MS, Thompson IM Jr, Goodman PJ, Kristal AR, Parnes HL, Lippman SM, Sutcliffe S, Peskoe SB, Barber JR, Drake CG, Nelson WG, De Marzo AM, Platz EA.

Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):463-9. doi: 10.1158/1055-9965.EPI-15-0987. Epub 2015 Dec 29.

14.

Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization.

Haffner MC, Weier C, Xu MM, Vaghasia A, Gürel B, Gümüşkaya B, Esopi DM, Fedor H, Tan HL, Kulac I, Hicks J, Isaacs WB, Lotan TL, Nelson WG, Yegnasubramanian S, De Marzo AM.

J Pathol. 2016 Jan;238(1):31-41. doi: 10.1002/path.4628. Epub 2015 Oct 14.

15.

Intraprostatic inflammation is positively associated with serum PSA in men with PSA <4 ng ml(-1), normal DRE and negative for prostate cancer.

Umbehr MH, Gurel B, Murtola TJ, Sutcliffe S, Peskoe SB, Tangen CM, Goodman PJ, Thompson IM, Lippman SM, Lucia MS, Parnes HL, Drake CG, Nelson WG, De Marzo AM, Platz EA.

Prostate Cancer Prostatic Dis. 2015 Sep;18(3):264-9. doi: 10.1038/pcan.2015.19. Epub 2015 May 5.

16.

Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention Trial.

Nash SH, Schenk JM, Kristal AR, Goodman PJ, Lucia MS, Parnes HL, Thompson IM, Lippman SM, Song X, Gurel B, De Marzo A, Platz EA.

Cancer Prev Res (Phila). 2015 Jul;8(7):590-6. doi: 10.1158/1940-6207.CAPR-14-0398. Epub 2015 Apr 29.

17.

Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial.

Gurel B, Lucia MS, Thompson IM Jr, Goodman PJ, Tangen CM, Kristal AR, Parnes HL, Hoque A, Lippman SM, Sutcliffe S, Peskoe SB, Drake CG, Nelson WG, De Marzo AM, Platz EA.

Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):847-56. doi: 10.1158/1055-9965.EPI-13-1126. Epub 2014 Apr 18.

18.

Effects of Ginkgo biloba extract on spinal cord ischemia-reperfusion injury in rats.

Badem S, Ugurlucan M, El H, Sahin M, Uysal M, Sayin OA, Gurel B, Basaran M, Bayindir C, Alpagut U, Dayioglu E.

Ann Vasc Surg. 2014 Jul;28(5):1296-305. doi: 10.1016/j.avsg.2014.02.020. Epub 2014 Feb 20.

PMID:
24561208
19.

Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion.

Gumuskaya B, Gurel B, Fedor H, Tan HL, Weier CA, Hicks JL, Haffner MC, Lotan TL, De Marzo AM.

Prostate Cancer Prostatic Dis. 2013 Jun;16(2):209-15. doi: 10.1038/pcan.2013.8. Epub 2013 Apr 2.

20.

Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome.

Hurley PJ, Marchionni L, Simons BW, Ross AE, Peskoe SB, Miller RM, Erho N, Vergara IA, Ghadessi M, Huang Z, Gurel B, Park BH, Davicioni E, Jenkins RB, Platz EA, Berman DM, Schaeffer EM.

Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):14977-82. doi: 10.1073/pnas.1203525109. Epub 2012 Aug 27.

21.

Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy.

Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, Olesen C, Gurel B, Demarzo AM, Wilding G, Carducci MA, Dionne CA, Møller JV, Nissen P, Christensen SB, Isaacs JT.

Sci Transl Med. 2012 Jun 27;4(140):140ra86. doi: 10.1126/scitranslmed.3003886. Erratum in: Sci Transl Med. 2012 Jul 18;4(143):143er4.

22.

Global levels of H3K27me3 track with differentiation in vivo and are deregulated by MYC in prostate cancer.

Pellakuru LG, Iwata T, Gurel B, Schultz D, Hicks J, Bethel C, Yegnasubramanian S, De Marzo AM.

Am J Pathol. 2012 Aug;181(2):560-9. doi: 10.1016/j.ajpath.2012.04.021. Epub 2012 Jun 17.

23.

An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy.

Antonarakis ES, Keizman D, Zhang Z, Gurel B, Lotan TL, Hicks JL, Fedor HL, Carducci MA, De Marzo AM, Eisenberger MA.

Cancer. 2012 Dec 15;118(24):6063-71. doi: 10.1002/cncr.27689. Epub 2012 Jun 6.

24.

High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity.

Haffner MC, Laimer J, Chaux A, Schäfer G, Obrist P, Brunner A, Kronberger IE, Laimer K, Gurel B, Koller JB, Seifarth C, Zelger B, Klocker H, Rasse M, Doppler W, Bander NH.

Mod Pathol. 2012 Aug;25(8):1079-85. doi: 10.1038/modpathol.2012.66. Epub 2012 Mar 30.

25.

PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients.

Lotan TL, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J, Hicks JL, Park BH, Humphreys E, Partin AW, Han M, Netto GJ, Isaacs WB, De Marzo AM.

Clin Cancer Res. 2011 Oct 15;17(20):6563-73. doi: 10.1158/1078-0432.CCR-11-1244. Epub 2011 Aug 30.

26.

Alterations in nucleolar structure and gene expression programs in prostatic neoplasia are driven by the MYC oncogene.

Koh CM, Gurel B, Sutcliffe S, Aryee MJ, Schultz D, Iwata T, Uemura M, Zeller KI, Anele U, Zheng Q, Hicks JL, Nelson WG, Dang CV, Yegnasubramanian S, De Marzo AM.

Am J Pathol. 2011 Apr;178(4):1824-34. doi: 10.1016/j.ajpath.2010.12.040.

27.

A case of prostatic adenocarcinoma with aberrant p63 expression: presentation with detailed immunohistochemical study and FISH analysis.

Baydar DE, Kulac I, Gurel B, De Marzo A.

Int J Surg Pathol. 2011 Feb;19(1):131-6. doi: 10.1177/1066896910379478. Epub 2010 Aug 18.

PMID:
20719821
28.

Can telomere alterations predict biochemical recurrence in prostate adenocarcinoma? A preliminary study.

Baydar DE, Ozen H, Geyik PO, Gurel B.

Pathol Res Pract. 2010 Oct 15;206(10):700-4. doi: 10.1016/j.prp.2010.05.009. Epub 2010 Jul 31.

PMID:
20674190
29.

Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements.

Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, Isaacs WB, Bova GS, Liu W, Xu J, Meeker AK, Netto G, De Marzo AM, Nelson WG, Yegnasubramanian S.

Nat Genet. 2010 Aug;42(8):668-75. doi: 10.1038/ng.613. Epub 2010 Jul 4.

30.

NKX3.1 as a marker of prostatic origin in metastatic tumors.

Gurel B, Ali TZ, Montgomery EA, Begum S, Hicks J, Goggins M, Eberhart CG, Clark DP, Bieberich CJ, Epstein JI, De Marzo AM.

Am J Surg Pathol. 2010 Aug;34(8):1097-105. doi: 10.1097/PAS.0b013e3181e6cbf3.

31.

Loss of Nkx3.1 expression in bacterial prostatitis: a potential link between inflammation and neoplasia.

Khalili M, Mutton LN, Gurel B, Hicks JL, De Marzo AM, Bieberich CJ.

Am J Pathol. 2010 May;176(5):2259-68. doi: 10.2353/ajpath.2010.080747. Epub 2010 Apr 2.

32.

Cell-autonomous intracellular androgen receptor signaling drives the growth of human prostate cancer initiating cells.

Vander Griend DJ, D'Antonio J, Gurel B, Antony L, Demarzo AM, Isaacs JT.

Prostate. 2010 Jan 1;70(1):90-9. doi: 10.1002/pros.21043.

33.

Langerhans' cell histiocytosis mimicking metastatic carcinoma of the lung.

Niksarlioglu YO, Gurel B, Tezel GG, Firat P, Dogan R, Kars A, Coplu L.

Respirology. 2009 Apr;14(3):456-8. doi: 10.1111/j.1440-1843.2008.01474.x. Epub 2009 Jan 27.

PMID:
19192223
34.

DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity.

Yegnasubramanian S, Haffner MC, Zhang Y, Gurel B, Cornish TC, Wu Z, Irizarry RA, Morgan J, Hicks J, DeWeese TL, Isaacs WB, Bova GS, De Marzo AM, Nelson WG.

Cancer Res. 2008 Nov 1;68(21):8954-67. doi: 10.1158/0008-5472.CAN-07-6088.

35.

Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets.

Gurel B, Iwata T, Koh CM, Yegnasubramanian S, Nelson WG, De Marzo AM.

Adv Anat Pathol. 2008 Nov;15(6):319-31. doi: 10.1097/PAP.0b013e31818a5c19. Review.

36.

Preventive effect of aminoguanidine compared to vitamin E and C on cisplatin-induced nephrotoxicity in rats.

Atasayar S, Gürer-Orhan H, Orhan H, Gürel B, Girgin G, Ozgüneş H.

Exp Toxicol Pathol. 2009 Jan;61(1):23-32. doi: 10.1016/j.etp.2008.04.016. Epub 2008 Aug 5.

PMID:
18684602
37.

Effect of montelukast and MK-886 on hepatic ischemia-reperfusion injury in rats.

Daglar G, Karaca T, Yuksek YN, Gozalan U, Akbiyik F, Sokmensuer C, Gurel B, Kama NA.

J Surg Res. 2009 May 1;153(1):31-8. doi: 10.1016/j.jss.2008.02.052. Epub 2008 Mar 26.

PMID:
18656901
38.

Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis.

Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C, Hicks JL, Morgan J, Cornish TC, Sutcliffe S, Isaacs WB, Luo J, De Marzo AM.

Mod Pathol. 2008 Sep;21(9):1156-67. doi: 10.1038/modpathol.2008.111. Epub 2008 Jun 20.

39.

Postinfantile giant cell hepatitis due to hepatitis E virus along with the presence of autoantibodies.

Harmanci O, Onal IK, Ersoy O, Gürel B, Sökmensüer C, Bayraktar Y.

Dig Dis Sci. 2007 Dec;52(12):3521-3. Epub 2007 Apr 5. No abstract available.

PMID:
17410455
40.

Benign mixed epithelial and stromal tumor of the kidney.

Ekici AI, Ekici S, Gürel B, Altinok G, Erkan I, Güngen Y.

ScientificWorldJournal. 2006 Jun 1;6:615-8.

Supplemental Content

Support Center